This edition of AACR Drug Discovery and Development (AACR D3) has already taken place.
Search future editions →Events › B2B Event
B2B Event
A specialized conference focused on accelerating cancer drug discovery and development, bringing together academic researchers, biotech/pharma professionals, and regulatory agencies. The 2026 event will focus on team-science approaches, novel therapeutics, and bridging discovery with clinical impact.
Planning for next year?
Dozens of solution providers here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.
Venue
Sheraton Boston HotelHotel venue · 5,744 m² · 26 halls · ~3,000 people
A 1,070-room hotel located in Boston's Back Bay, featuring over 61,000 sq ft of meeting space across 26 rooms, with direct access to the Hynes Convention Center.
📍 39 Dalton St, Boston, MA 02199, USA
Operated by Marriott International
Organizer
American Association for Cancer ResearchNonprofit · Philadelphia, United States · Founded 1907
The first and largest cancer research organization dedicated to accelerating the prevention and cure of cancer.
Why people attend
To evaluate new therapeutic platforms, find collaborative partners, and explore specialized services in the oncology pipeline.
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
154 speakers at AACR Drug Discovery and Development (AACR D3)
Speaker of the U.S. House of Representatives · U.S. House of Representatives
"Opening Ceremony Remarks"
U.S. Rep. Nancy P. Pelosi (D-California), speaker of the U.S. House of Representatives, will receive the 2021 AACR Distinguished Public Service Award in recognition of her leadership as a champion for science-related issues. Throughout her distinguished congressional career, Pelosi has consistently advocated for robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
Director · National Cancer Institute
"NCI Director’s Address"
Norman E. “Ned” Sharpless, MD, FAACR, is the director of the National Cancer Institute (NCI).
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
President · American Association for Cancer Research
"Fireside Chat with NCI Director Norman E. Sharpless"
Antoni Ribas, MD, PhD, FAACR, is the President of the American Association for Cancer Research (AACR).
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
Deputy Director for Scientific Strategy and Development · National Cancer Institute
"Progress and the Future of the Cancer Moonshot"
Dinah S. Singer, PhD, is the deputy director for scientific strategy and development at the National Cancer Institute (NCI).
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
Director of the Center for Tobacco Products · U.S. Food and Drug Administration
"Issues Important to Tobacco Control"
Mitch Zeller is the director of the Center for Tobacco Products at the U.S. Food and Drug Administration.
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
Director of the Division of Cancer Prevention and Control · Centers for Disease Control and Prevention
"Building Vaccine Confidence: Best Practices to Combat Misinformation and Vaccine Hesitancy in COVID-19 Vaccines"
Lisa Richardson, MD, MPH, is the director of the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention.
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
Annual Meeting Program Chair · American Association for Cancer Research (AACR)
"Virtual AACR Annual Meeting 2021 Press Conference"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
Co-director · San Antonio Breast Cancer Symposium
"Virtual SABCS Press Conference"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact
Co-director · San Antonio Breast Cancer Symposium
"Virtual SABCS Press Conference"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact
Director · National Institute of Allergy and Infectious Diseases (NIAID)
"Coronavirus infections: More than just the common cold"
Also speaking at World Molecular Imaging Congress, Advances in Malignant Lymphoma: From Discovery to Clinical Impact, Critical Care Congress
Icahn School of Medicine at Mount Sinai
"The crosstalk between cellular transformation and the response to SARS-CoV-2 infection"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
National Institute of Allergy and Infectious Diseases
"Rapid SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
National Cancer Institute
"Inhibition of Bruton Tyrosine Kinase in patients with severe COVID-19"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
CHU Vaudois, Lausanne, Switzerland
"Flexibility to sustain solidity: Addressing new vulnerabilities in cancer at the time of COVID-19"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
University of California, San Francisco
"Leveraging new insights from cancer drug discovery to target viral host factors"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
NYU Langone Health
"Ethics, cancer and COVID"
Also speaking at Advances in Malignant Lymphoma: From Discovery to Clinical Impact, AACR Special Conference: Breaking Barriers in the Fight Against Rare Cancers
+ 138 more speakers at this event.
More events in United States
Frequently asked questions